OBN Awards Crown Synpromics ‘Best Emerging UK Synthetic Biotech Company’
Image credit: Synpromics
Synpromics is thrilled to announce they have been awarded Best Emerging UK Synthetic Biotech Company at the 9th Annual OBN Awards celebration last night. Synpromics was nominated on the strength of being the leader in gene control, improving human health by enabling safer, more effective cell and gene medicines through proprietary genomics, bioinformatics and intelligent data-driven design.
The OBN Awards celebrate innovation and outstanding achievement across the UK Life Sciences industry, including emerging to late-stage R&D companies as well as life science investors. The Awards cover Biotech, Medtech, Synthetic Biology and Digital Health.
Receiving the award, Michael Roberts, Founder & CSO of Synpromics, commented: ‘We could not be happier with the outcome of last night’s Awards. This accolade is testament to the significant progress we have made over the past year, in growing our business by expanding the number of partnerships that we have with top pharma and biotech companies and significantly expanding our team.’
Synpromics would like to thank OBN for organising The Awards, and SynbiCITE for sponsoring this award.
This article has been republished from materials provided by Synpromics. Note: material may have been edited for length and content. For further information, please contact the cited source.
Forensic Evidence Shows Newfoundland was Populated Multiple Times by Distinct GroupsNews
Analysis of tiny amounts of bone or teeth from ancient remains showed that groups of indigenous people from Newfoundland had distinct population histories.READ MORE
Multi-tissue, Multi-individual Data Used to Identify Mechanisms of Gene RegulationNews
Developing a mechanistic model for how healthy bodies function and how certain diseases merge may now be possible.READ MORE
Biomarker for Glioblastoma Predicts Clinical Course and Sensitivity to TreatmentNews
Scientists validate a biomarker indicative of patients with Glioblastoma prognosis and likely response to specific therapies.READ MORE